|
Content :
Fighting corruption
Background
Today organizations are aware of the harmful consequences of corruption on international business transactions and the world economy. Corruption is a deterrent to economic development in general, particularly in emerging countries because it undermines fair competition among economic players and destroys public trust. Over the past few years, authorities in the United States and in Europe have increased their scrutiny of the healthcare sector. As a consequence, healthcare companies may find themselves particularly vulnerable with regard to specific practices in the industry. For several years now, Sanofi has implemented appropriate measures and tools to prevent and fight corruption in all countries where the Group does business. Solid guidelinesFighting corruption requires international rules adhered to by as many countries as possible, as well as effective anti-corruption legislation enforced nationally. The adoption of the Organization for Economic Cooperation and Development (OECD) and United Nations (UN) conventions against corruption and national laws with very broad coverage, such as the U.S. Foreign Corrupt Practices Act (FCPA) and the U.K. Bribery Act, contributes to achieving this goal. Fighting corruption also requires multinational companies to play an active role by helping ensure a level playing field. To ensure ethical conduct, Sanofi adheres to: The external reference principles of the United Nations Global Compact (Principle 10) The United Nations Convention against Corruption - adopted on 31 October 2003 The Organization for Economic Cooperation and Development (OECD) Convention on Combating Bribery of Foreign Public Officials in International Business Transactions Measures adopted in application of the U.S. Sarbanes-Oxley Act (Section 301)
|
